Ohrnberger C E, Khan S A, Meisheri K D
Upjohn Laboratories, Kalamazoo, Michigan.
J Pharmacol Exp Ther. 1993 Oct;267(1):25-30.
Glyburide, a sulfonylurea, and U-37883A, a guanidine (4-Morpholinecarboximidine-N-1-Adamantyl-N' cyclohexylhydrochloride), have been previously characterized as antagonists of the vascular ATP-sensitive K+ channels (KATP). In this report, the in vitro interaction between these two chemically distinct KATP antagonists was investigated using isolated rabbit mesenteric artery. The KATP antagonism was functionally studied as the inhibition of vasodilation produced by various KATP openers as follows: pinacidil (1 microM), minoxidil sulfate (5 microM), cromakalim (0.5 microM) and RP-49356 (1 microM). Glyburide alone produced inhibition in the concentration range of 50 to 500 nM with the glyburide IC50 ranging from 72 to 148 nM. U-37883A alone produced inhibition in the concentration range of 0.5 to 5 microM, with the U-37883A IC50 ranging from 0.78 to 1.4 microM. In the presence of a threshold U-37883A concentration of 0.5 microM, the glyburide inhibition dose-response curve against pinacidil was significantly shifted to the left and the glyburide IC50 was lowered from 72 to 3.9 nM, representing an 18-fold decrease. Similarly, in the presence of a threshold glyburide concentration of 50 nM, the U-37883A inhibition dose-response curve against pinacidil was significantly shifted to the left and the U-37883A IC50 was lowered from 780 to 96 nM, representing an eightfold decrease. Thus, glyburide and U-37883A potentiated each other's effects as KATP blockers. This synergistic interaction between glyburide and U-37883A was observed independently of the pinacidil, cromakalim or minoxidil sulfate used to produce vasodilation.(ABSTRACT TRUNCATED AT 250 WORDS)
格列本脲(一种磺酰脲类药物)和U - 37883A(一种胍类化合物,4 - 吗啉甲脒 - N - 1 - 金刚烷基 - N' - 环己基盐酸盐),先前已被表征为血管ATP敏感性钾通道(KATP)的拮抗剂。在本报告中,使用离体兔肠系膜动脉研究了这两种化学性质不同的KATP拮抗剂之间的体外相互作用。通过抑制各种KATP开放剂产生的血管舒张来对KATP拮抗作用进行功能研究,这些KATP开放剂如下:吡那地尔(1微摩尔)、硫酸米诺地尔(5微摩尔)、克罗卡林(0.5微摩尔)和RP - 49356(1微摩尔)。单独使用格列本脲在50至500纳摩尔浓度范围内产生抑制作用,格列本脲的IC50范围为72至148纳摩尔。单独使用U - 37883A在0.5至5微摩尔浓度范围内产生抑制作用,U - 37883A的IC50范围为0.78至1.4微摩尔。在存在阈值浓度0.5微摩尔的U - 37883A时,格列本脲针对吡那地尔的抑制剂量 - 反应曲线显著左移,格列本脲的IC50从72纳摩尔降至3.9纳摩尔,降低了18倍。同样,在存在阈值浓度50纳摩尔的格列本脲时,U - 37883A针对吡那地尔的抑制剂量 - 反应曲线显著左移,U - 37883A的IC50从780纳摩尔降至96纳摩尔,降低了8倍。因此,格列本脲和U - 37883A作为KATP阻滞剂相互增强彼此的作用。格列本脲和U - 37883A之间的这种协同相互作用与用于产生血管舒张的吡那地尔、克罗卡林或硫酸米诺地尔无关。(摘要截短为250字)